Lopinavir/r or Fosamprenavir/r Switch to Atazanavir/r or Darunavir/r (LARD)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00756730 |
Recruitment Status
:
Completed
First Posted
: September 22, 2008
Results First Posted
: July 13, 2012
Last Update Posted
: August 21, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infections | Drug: ATV/r Drug: DRV/r | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 49 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Randomized, Open-label Study of Switch From Lopinavir/Ritonavir (LPV/r) or Fosamprenavir/Ritonavir (FPV/r) to Either Once Daily Atazanavir/Ritonavir (ATV/r) or Once Daily Darunavir/Ritonavir (DRV/r) (Plus Background Nucleoside Reverse Transcriptase Inhibitors) in Patients Experiencing Triglyceride Elevations While Receiving LPV/r or FPV/r. |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | June 2011 |
Actual Study Completion Date : | June 2011 |

Arm | Intervention/treatment |
---|---|
Switch to DRV/r (800mg/100mg) QD
We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this arm the sbject switched to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
|
Drug: DRV/r
We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
|
Switch to ATV/r (300mg/100mg QD)
We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. For this are the subject switched to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study
|
Drug: ATV/r
Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
Other Name: Atazanavir/r
|
- Percentage of Patients That Experience 10% Decline in Triglycerides From Baseline to Week 24. [ Time Frame: baseline, 24 weeks ]A 10% decline in triglycerides (TGs) was determined to be clinically significant. The percentage of people that experienced a 10% decline was calculated by dividing the number who had a decline of 10% TGs by the total number of participants in the arm.
- At Week 24 the Percentage of Subjects That Had Triglycerides Less Than 200 mg/dL [ Time Frame: 24 weeks ]
- The Change in Fasting Triglyceride Level From Baseline to Week 24 [ Time Frame: Baseline to week 24 ]
- Percent of Patients With HIV VL <200 Copies/mL at Week 4, 12 & 24 [ Time Frame: Week 4, 12 & 24 ]
- Difference in CD4 From Baseline to Week 24 [ Time Frame: baseline to Week 24 ]
- Total Cholesterol in the Two Study Groups at 24 Weeks [ Time Frame: Week 24 ]
- LDL Cholesterol at Week 24 [ Time Frame: week 24 ]
- HDL Cholesterol at Week 24 [ Time Frame: 24 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Currently receiving Antiretroviral Therapy (ART) regimen including LPV/r or FPV/r and > or equal to 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs). Patient must be on a stable regimen containing LPV/r or FPV/r for at least 12 weeks prior to screening.
- Documentation of an undetectable Human Immunodeficiency Virus (HIV) viral load (VL<400 copies/ml) using an FDA approved assay for a minimum of twelve weeks prior to screening AND undetectable HIV viral load using an FDA approved ultrasensitive assay at screening.
- No evidence of HIV protease resistance as defined by the Stanford HIV database
- Currently receiving first protease inhibitor unless switch to LPV/r or FPV/r was for non-virologic reasons
- Fasting triglycerides > 200 mg/dL
- No ongoing issues that in the opinion of the investigator would lead to decreased ability to comply with the study procedures
- If currently receiving a proton pump inhibitor, the dose is < omeprazole 20 mg or the equivalent dose of another proton pump inhibitor
- If patient is receiving another lipid lowering medication, it must be at a stable dose
Exclusion Criteria:
- Currently receiving an ART regimen other than > or equal to two NRTIs and either LPV/r or FPV/r
- Prior use of darunavir or atazanavir
- CDC Class C Illness diagnosed within 30 days of screening
- Patient is currently receiving the following Hydroxamethylglutaryl-coA (HMGCoA) reductase inhibitor medications (statins): pravastatin, lovastatin, simvastatin
- Patient is currently receiving a bile acid sequestrant (cholestyramine, colestipol, and colesevelam)
-
Grade 3 or 4 Laboratory abnormalities as defined by a standardized grading scheme based on the DAIDS table with the following exceptions:
- Pre-existing diabetes mellitus with asymptomatic, nonfasting glucose grade 3 elevations
- Subjects with asymptomatic grade 3 fasting triglyceride or cholesterol elevations
- Clinical or laboratory evidence of clinically significant liver impairment/dysfunction disease or cirrhosis
- Note: Individuals co-infected with chronic hepatitis B or C viruses will be allowed to enter the trial if their condition is clinically stable and they will not require therapy during the course of the study. Individuals diagnosed with acute viral hepatitis at screening will not be allowed to enroll during acute phase
- Active substance abuse or significant psychiatric illness that in the opinion of the investigator might interfere with study compliance
- Use of any investigational agents 30 days prior to screening
- Life expectancy < 6 months in the opinion of the investigator
- Pregnancy or breast feeding
- Female subject of childbearing potential (i.e., heterosexually active, and not surgically sterile or at least two years post-menopausal) not using effective non-hormonal birth control methods or not willing to continue practicing these birth control methods from screening until the last trial related activity

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00756730
United States, Arizona | |
Spectrum Medical Group | |
Phoenix, Arizona, United States, 85012 | |
United States, California | |
AIDS Healthcare Foundation | |
Los Angeles, California, United States, 02319 | |
United States, Florida | |
Orlando Immunology Center | |
Orlando, Florida, United States, 32803 | |
United States, Massachusetts | |
Community Research Initiative | |
Boston, Massachusetts, United States, 02215 | |
Community Research Initiative - West | |
Springfield, Massachusetts, United States, 01107 | |
United States, Minnesota | |
Abbott Northwestern Infectious Disease and Travel Clinic | |
Minneapolis, Minnesota, United States, 55404 | |
United States, New York | |
AIDS Community Health Center | |
Rochester, New York, United States, 14804 | |
United States, Pennsylvania | |
Philadelphia Fight | |
Philadelphia, Pennsylvania, United States, 19107 | |
United States, Texas | |
David M. Lee, M.D., P.A., a/b/a Uptown Physicians Group | |
Dallas, Texas, United States, 75204 | |
Nicholaos C. Bellos, MD, PA | |
Dallas, Texas, United States, 75204 | |
United States, Wisconsin | |
Medical College of Wisconsin | |
Milwaukee, Wisconsin, United States, 53226 |
Principal Investigator: | Daniel J Skiest, MD | Community Research Initiative |
Responsible Party: | Community Research Initiative of New England |
ClinicalTrials.gov Identifier: | NCT00756730 History of Changes |
Other Study ID Numbers: |
08-09 |
First Posted: | September 22, 2008 Key Record Dates |
Results First Posted: | July 13, 2012 |
Last Update Posted: | August 21, 2017 |
Last Verified: | July 2017 |
Keywords provided by Community Research Initiative of New England:
lopinavir ritonavir atazanavir fosamprenavir darunavir anti-retroviral |
AIDS HIV LARD triglyceride protease inhibitors treatment Experienced |
Additional relevant MeSH terms:
HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Ritonavir Lopinavir Darunavir Atazanavir Sulfate Fosamprenavir Benzocaine |
Reverse Transcriptase Inhibitors HIV Protease Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents Cytochrome P-450 CYP3A Inhibitors Cytochrome P-450 Enzyme Inhibitors Anesthetics, Local Anesthetics Central Nervous System Depressants Physiological Effects of Drugs |